ImmunityBio initiates phase 2 "chemo-free" lymphoma trial
Share
ImmunityBio (NASDAQ:IBRX) announced Monday the launch of ResQ215B, a Phase 2 clinical study evaluating a novel, outpatient immunotherapy combination for patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia.
